Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study

Published:2018-01 Issue: Volume:88 Page:57-66
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Gaspar Nathalie,Occean Bob-Valéry^ORCID,Pacquement Hélène,Bompas Emmanuelle,Bouvier Corine,Brisse Hervé J.^ORCID,Castex Marie-Pierre,Cheurfa Nadir,Corradini Nadège,Delaye Jessy,Entz-Werlé Natacha,Gentet Jean-Claude,Italiano Antoine,Lervat Cyril,Marec-Berard Perrine,Mascard Eric,Redini Françoise,Saumet Laure,Schmitt Claudine,Tabone Marie-Dominique,Verite-Goulard Cécile,Le Deley Marie-Cécile,Piperno-Neumann Sophie,Brugieres Laurence^ORCID

Funder

French National Cancer Institute (INCa)

NOVARTIS

Chugai

Ligue Nationale contre le Cancer

Fédération Enfants et Santé

Société Française des Cancers et Leucémies de l'Enfant

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate;Meyers;J Clin Oncol,2005

2. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the Children's Oncology Group;Meyers;J Clin Oncol Off J Am Soc Clin Oncol,2008

3. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment;Whelan;Ann Oncol,2015

4. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

5. Osteosarcoma: current treatment and a collaborative pathway to success;Isakoff;J Clin Oncol,2015

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A useful mTORC1 signaling-related RiskScore model for the personalized treatment of osteosarcoma patients by using the bulk RNA-seq analysis;Discover Oncology;2024-09-09

2. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO;European Journal of Cancer;2024-09

3. Intratumoral Heterogeneity Assessment of the Extracellular Bone Matrix and Immune Microenvironment in Osteosarcoma Using Digital Imaging to Predict Therapeutic Response;Laboratory Investigation;2024-09

4. The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma;BMC Cancer;2024-08-01

5. Lycorine combined with cisplatin synergistically inhibited osteosarcoma cells growth and metastasis by suppressing Wnt/β-Catenin and STAT3 signaling pathways;Journal of Functional Foods;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3